Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation

330Citations
Citations of this article
288Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

AimsCongenital long QT syndromes (LQTSs) are associated with prolonged ventricular repolarization and sudden cardiac death. Limitations to existing clinical therapeutic management strategies prompted us to develop a novel human in vitro drug-evaluation system for LQTS type 2 (LQT2) that will complement the existing in vitro and in vivo models.Methods and resultsSkin fibroblasts from a patient with a KCNH2 G1681A mutation (encodes IKr potassium ion channel) were reprogrammed to human induced pluripotent stem cells (hiPSCs), which were subsequently differentiated to functional cardiomyocytes. Relative to controls (including the patients mother), multi-electrode array and patch-clamp electrophysiology of LQT2hiPSC cardiomyocytes showed prolonged field/action potential duration. When LQT2hiPSC cardiomyocytes were exposed to E4031 (an IKr blocker), arrhythmias developed and these presented as early after depolarizations (EADs) in the action potentials. In contrast to control cardiomyocytes, LQT2hiPSC cardiomyocytes also developed EADs when challenged with the clinically used stressor, isoprenaline. This effect was reversed by β-blockers, propranolol, and nadolol, the latter being used for the patients therapy. Treatment of cardiomyocytes with experimental potassium channel enhancers, nicorandil and PD118057, caused action potential shortening and in some cases could abolish EADs. Notably, combined treatment with isoprenaline (enhancers/isoprenaline) caused EADs, but this effect was reversed by nadolol.ConclusionsFindings from this paper demonstrate that patient LQT2hiPSC cardiomyocytes respond appropriately to clinically relevant pharmacology and will be a valuable human in vitro model for testing experimental drug combinations. © 2010 The Author.

References Powered by Scopus

Induced pluripotent stem cell lines derived from human somatic cells

8769Citations
N/AReaders
Get full text

Drug-Induced Prolongation of the QT Interval

1759Citations
N/AReaders
Get full text

Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias

1572Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming

539Citations
N/AReaders
Get full text

Pluripotent stem cells in disease modelling and drug discovery

463Citations
N/AReaders
Get full text

Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity

447Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Matsa, E., Rajamohan, D., Dick, E., Young, L., Mellor, I., Staniforth, A., & Denning, C. (2011). Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. European Heart Journal, 32(8), 952–962. https://doi.org/10.1093/eurheartj/ehr073

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 118

56%

Researcher 68

32%

Professor / Associate Prof. 22

10%

Lecturer / Post doc 2

1%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 94

44%

Biochemistry, Genetics and Molecular Bi... 53

25%

Medicine and Dentistry 46

21%

Engineering 23

11%

Save time finding and organizing research with Mendeley

Sign up for free